ERS10862281 SAMEA13259304 10090 Mus musculus Protocols: CD8 T cells were isolated via FACS seven days post addition of tamoxifen. We employed intracranial (i.c.) infection of adult GFAP:GP mice with rLCMV-GP33 as an experimental model of transient viral infection of the brain to generate GP33-specific tissue-resident memory CD8+ T cells (TRM). Cross-reactivity of TRM with a CNS-restricted self-antigen was modeled by the TAM-inducible expression of LCMV glycoprotein (GP) antigens in a CNS-restricted cell population (astrocytes). For depletion of circulating CD8+ T cells or CD4+ T cells, mice were treated intraperitoneally twice over a 3 days interval with 200 μg of rat-anti-mouse-CD8α-depleting antibody (BioXCell, BE0117), 250 μg of rat-anti-mouse-CD4 -depleting antibody (home-made, clone YTS191) or isotype control (BioXCell, BE0090).Anti-CD8 was administered 7 and 4 days before start of TAM while anti-CD4 was administered 4 and 1 day prior start of TAM. For relapse experiments, mice were treated intraperitoneally with 200 μg of mouse-anti-mouse-CD8α -depleting antibody (Ab00166-2.0, Absolute Antibody) or isotype control (Ab00166-2.3, Absolute Antibody) 7 and 4 days before each TAM administration. According to 10x 3' protocol According to 10x 3' protocol ENA first public 2022-03-14 ENA last update 2022-03-14 External Id SAMEA13259304 INSDC center alias ETH ZURICH INSDC center name ETH ZURICH INSDC first public 2022-03-14T00:28:36Z INSDC last update 2022-03-14T00:28:36Z INSDC status public Submitter Id E-MTAB-11511:Sample 1 age 8 broker name ArrayExpress cell type T cell common name house mouse developmental stage adult genotype GFAP-CreERT2tg/+:Stop-GPflox/+ organism part brain sample name E-MTAB-11511:Sample 1 sex male stimulus CD4 and CD8 depletion via antibody before TAM induction strain C57BL6 ERS10862282 SAMEA13259305 10090 Mus musculus Protocols: CD8 T cells were isolated via FACS seven days post addition of tamoxifen. We employed intracranial (i.c.) infection of adult GFAP:GP mice with rLCMV-GP33 as an experimental model of transient viral infection of the brain to generate GP33-specific tissue-resident memory CD8+ T cells (TRM). Cross-reactivity of TRM with a CNS-restricted self-antigen was modeled by the TAM-inducible expression of LCMV glycoprotein (GP) antigens in a CNS-restricted cell population (astrocytes). For depletion of circulating CD8+ T cells or CD4+ T cells, mice were treated intraperitoneally twice over a 3 days interval with 200 μg of rat-anti-mouse-CD8α-depleting antibody (BioXCell, BE0117), 250 μg of rat-anti-mouse-CD4 -depleting antibody (home-made, clone YTS191) or isotype control (BioXCell, BE0090).Anti-CD8 was administered 7 and 4 days before start of TAM while anti-CD4 was administered 4 and 1 day prior start of TAM. For relapse experiments, mice were treated intraperitoneally with 200 μg of mouse-anti-mouse-CD8α -depleting antibody (Ab00166-2.0, Absolute Antibody) or isotype control (Ab00166-2.3, Absolute Antibody) 7 and 4 days before each TAM administration. According to 10x 3' protocol According to 10x 3' protocol ENA first public 2022-03-14 ENA last update 2022-03-14 External Id SAMEA13259305 INSDC center alias ETH ZURICH INSDC center name ETH ZURICH INSDC first public 2022-03-14T00:28:36Z INSDC last update 2022-03-14T00:28:36Z INSDC status public Submitter Id E-MTAB-11511:Sample 2 age 8 broker name ArrayExpress cell type T cell common name house mouse developmental stage adult genotype GFAP-CreERT2tg/+:Stop-GPflox/+ organism part brain sample name E-MTAB-11511:Sample 2 sex male stimulus CD4 and CD8 depletion via antibody before TAM induction strain C57BL6 ERS10862283 SAMEA13259306 10090 Mus musculus Protocols: CD8 T cells were isolated via FACS seven days post addition of tamoxifen. We employed intracranial (i.c.) infection of adult GFAP:GP mice with rLCMV-GP33 as an experimental model of transient viral infection of the brain to generate GP33-specific tissue-resident memory CD8+ T cells (TRM). Cross-reactivity of TRM with a CNS-restricted self-antigen was modeled by the TAM-inducible expression of LCMV glycoprotein (GP) antigens in a CNS-restricted cell population (astrocytes). For depletion of circulating CD8+ T cells or CD4+ T cells, mice were treated intraperitoneally twice over a 3 days interval with 200 μg of rat-anti-mouse-CD8α-depleting antibody (BioXCell, BE0117), 250 μg of rat-anti-mouse-CD4 -depleting antibody (home-made, clone YTS191) or isotype control (BioXCell, BE0090).Anti-CD8 was administered 7 and 4 days before start of TAM while anti-CD4 was administered 4 and 1 day prior start of TAM. For relapse experiments, mice were treated intraperitoneally with 200 μg of mouse-anti-mouse-CD8α -depleting antibody (Ab00166-2.0, Absolute Antibody) or isotype control (Ab00166-2.3, Absolute Antibody) 7 and 4 days before each TAM administration. According to 10x 3' protocol According to 10x 3' protocol ENA first public 2022-03-14 ENA last update 2022-03-14 External Id SAMEA13259306 INSDC center alias ETH ZURICH INSDC center name ETH ZURICH INSDC first public 2022-03-14T00:28:36Z INSDC last update 2022-03-14T00:28:36Z INSDC status public Submitter Id E-MTAB-11511:Sample 3 age 8 broker name ArrayExpress cell type T cell common name house mouse developmental stage adult genotype GFAP-CreERT2tg/+:Stop-GPflox/+ organism part brain sample name E-MTAB-11511:Sample 3 sex male stimulus CD8 depletion via antibody before TAM induction strain C57BL6 ERS10862284 SAMEA13259307 10090 Mus musculus Protocols: CD8 T cells were isolated via FACS seven days post addition of tamoxifen. We employed intracranial (i.c.) infection of adult GFAP:GP mice with rLCMV-GP33 as an experimental model of transient viral infection of the brain to generate GP33-specific tissue-resident memory CD8+ T cells (TRM). Cross-reactivity of TRM with a CNS-restricted self-antigen was modeled by the TAM-inducible expression of LCMV glycoprotein (GP) antigens in a CNS-restricted cell population (astrocytes). For depletion of circulating CD8+ T cells or CD4+ T cells, mice were treated intraperitoneally twice over a 3 days interval with 200 μg of rat-anti-mouse-CD8α-depleting antibody (BioXCell, BE0117), 250 μg of rat-anti-mouse-CD4 -depleting antibody (home-made, clone YTS191) or isotype control (BioXCell, BE0090).Anti-CD8 was administered 7 and 4 days before start of TAM while anti-CD4 was administered 4 and 1 day prior start of TAM. For relapse experiments, mice were treated intraperitoneally with 200 μg of mouse-anti-mouse-CD8α -depleting antibody (Ab00166-2.0, Absolute Antibody) or isotype control (Ab00166-2.3, Absolute Antibody) 7 and 4 days before each TAM administration. According to 10x 3' protocol According to 10x 3' protocol ENA first public 2022-03-14 ENA last update 2022-03-14 External Id SAMEA13259307 INSDC center alias ETH ZURICH INSDC center name ETH ZURICH INSDC first public 2022-03-14T00:28:36Z INSDC last update 2022-03-14T00:28:36Z INSDC status public Submitter Id E-MTAB-11511:Sample 4 age 8 broker name ArrayExpress cell type T cell common name house mouse developmental stage adult genotype GFAP-CreERT2tg/+:Stop-GPflox/+ organism part brain sample name E-MTAB-11511:Sample 4 sex male stimulus CD8 depletion via antibody before TAM induction strain C57BL6 ERS10862285 SAMEA13259308 10090 Mus musculus Protocols: CD8 T cells were isolated via FACS seven days post addition of tamoxifen. We employed intracranial (i.c.) infection of adult GFAP:GP mice with rLCMV-GP33 as an experimental model of transient viral infection of the brain to generate GP33-specific tissue-resident memory CD8+ T cells (TRM). Cross-reactivity of TRM with a CNS-restricted self-antigen was modeled by the TAM-inducible expression of LCMV glycoprotein (GP) antigens in a CNS-restricted cell population (astrocytes). For depletion of circulating CD8+ T cells or CD4+ T cells, mice were treated intraperitoneally twice over a 3 days interval with 200 μg of rat-anti-mouse-CD8α-depleting antibody (BioXCell, BE0117), 250 μg of rat-anti-mouse-CD4 -depleting antibody (home-made, clone YTS191) or isotype control (BioXCell, BE0090).Anti-CD8 was administered 7 and 4 days before start of TAM while anti-CD4 was administered 4 and 1 day prior start of TAM. For relapse experiments, mice were treated intraperitoneally with 200 μg of mouse-anti-mouse-CD8α -depleting antibody (Ab00166-2.0, Absolute Antibody) or isotype control (Ab00166-2.3, Absolute Antibody) 7 and 4 days before each TAM administration. According to 10x 3' protocol According to 10x 3' protocol ENA first public 2022-03-14 ENA last update 2022-03-14 External Id SAMEA13259308 INSDC center alias ETH ZURICH INSDC center name ETH ZURICH INSDC first public 2022-03-14T00:28:36Z INSDC last update 2022-03-14T00:28:36Z INSDC status public Submitter Id E-MTAB-11511:Sample 5 age 8 broker name ArrayExpress cell type T cell common name house mouse developmental stage adult genotype Stop-GPflox organism part brain sample name E-MTAB-11511:Sample 5 sex male stimulus StopGP - no TAM reactivation strain C57BL6 ERS10862286 SAMEA13259309 10090 Mus musculus Protocols: CD8 T cells were isolated via FACS seven days post addition of tamoxifen. We employed intracranial (i.c.) infection of adult GFAP:GP mice with rLCMV-GP33 as an experimental model of transient viral infection of the brain to generate GP33-specific tissue-resident memory CD8+ T cells (TRM). Cross-reactivity of TRM with a CNS-restricted self-antigen was modeled by the TAM-inducible expression of LCMV glycoprotein (GP) antigens in a CNS-restricted cell population (astrocytes). For depletion of circulating CD8+ T cells or CD4+ T cells, mice were treated intraperitoneally twice over a 3 days interval with 200 μg of rat-anti-mouse-CD8α-depleting antibody (BioXCell, BE0117), 250 μg of rat-anti-mouse-CD4 -depleting antibody (home-made, clone YTS191) or isotype control (BioXCell, BE0090).Anti-CD8 was administered 7 and 4 days before start of TAM while anti-CD4 was administered 4 and 1 day prior start of TAM. For relapse experiments, mice were treated intraperitoneally with 200 μg of mouse-anti-mouse-CD8α -depleting antibody (Ab00166-2.0, Absolute Antibody) or isotype control (Ab00166-2.3, Absolute Antibody) 7 and 4 days before each TAM administration. According to 10x 3' protocol According to 10x 3' protocol ENA first public 2022-03-14 ENA last update 2022-03-14 External Id SAMEA13259309 INSDC center alias ETH ZURICH INSDC center name ETH ZURICH INSDC first public 2022-03-14T00:28:36Z INSDC last update 2022-03-14T00:28:36Z INSDC status public Submitter Id E-MTAB-11511:Sample 6 age 8 broker name ArrayExpress cell type T cell common name house mouse developmental stage adult genotype Stop-GPflox organism part brain sample name E-MTAB-11511:Sample 6 sex male stimulus StopGP - no TAM reactivation strain C57BL6